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Aims To evaluate oral doses of the non-steroidal mineralocorticoid receptor antagonist finerenone given for 90 days in patients
with worsening heart failure and reduced ejection fraction and chronic kidney disease and/or diabetes mellitus.
Methods
and results
Miner Alocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF) was a randomized, double-blind,
phase 2b multicentre study (ClinicalTrials.gov: NCT01807221). Of 1286 screened patients, 1066 were randomized. Pa-
tients received oral, once-daily finerenone (2.5, 5, 7.5, 10, or 15 mg, uptitrated to 5, 10, 15, 20, or 20 mg, respectively, on
Day 30) or eplerenone (25 mg every other day, increased to 25 mg once daily on Day 30, and to 50 mg once daily on Day
60) for 90 days. The primary endpoint was the percentage of individuals with a decrease of .30% in plasma N-terminal
pro-B-type natriuretic peptide (NT-proBNP) from baseline to Day 90. A key exploratory endpoint was a composite
clinical endpoint of death from any cause, cardiovascular hospitalizations, or emergency presentation for worsening HF
until Day 90. Mean age ranged from 69.2 to 72.5 years in different treatment groups (standard deviation 9.7–10.6 years).
Decreases in NT-proBNP of .30% from baseline occurred in 37.2% of patients in the eplerenone group and 30.9,
32.5, 37.3, 38.8, and 34.2% in the 2.55, 510, 7.515, 1020, and 1520 mg finerenone groups, respectively
(P ¼ 0.42–0.88). Except for the 2.55 mg finerenone group, the composite clinical endpoint occurred numerically
less frequently in finerenone-treated patients compared with eplerenone; this difference reached nominal statistical
significance in the 1020 mg group (hazard ratio 0.56, 95% confidence interval, CI, 0.35; 0.90; nominal P ¼ 0.02),
despite the fact that this phase 2 study was not designed to detect statistical significant differences. A potassium level in-
crease to ≥5.6 mmol/L at any time point occurred in 4.3% of patients, with a balanced distribution among all treatment
groups.
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Conclusion Finerenone was well tolerated and induced a 30% or greater decrease in NT-proBNP levels in a similar proportion of
patients to eplerenone. The finding of reduced clinical events in the finerenone 1020 mg group should be further
explored in a large outcomes trial.
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Introduction
The steroidal mineralocorticoid receptor antagonists (MRAs) spir-
onolactone1 and eplerenone2 reduce mortality and hospitalizations
in patients with heart failure with reduced ejection fraction (HFrEF),
and are recommended in European and US guidelines for symptom-
atic patients with HFrEF.3,4 While both spironolactone and eplere-
none have been shown to be effective in patients with HFrEF, they
may be underused or inconsistently prescribed in hospitalized pa-
tients with worsening heart failure (HF) because of a high risk of ad-
verse events.5,6 Furthermore, patients with common co-morbidities
of HF such as diabetes mellitus (DM) or chronic kidney disease
(CKD) are at particular risk of developing hyperkalemia,7 so may
be less likely to receive currently available MRA therapy due to
safety concerns. Thus, there is an unmet medical need in patients
with worsening HFrEF, and impaired kidney function, which is not
being met using currently available MRAs.
Finerenone (BAY 94-8862) is a novel non-steroidal MRA, with
higher selectivity towards the mineralocorticoid receptor (MR)
compared with spironolactone and stronger MR-binding affinity
than eplerenone.8 This combination of potency and selectivity to-
wards the MR9 and a balanced tissue distribution into heart and
kidney compared with spironolactone or eplerenone10 could re-
sult in more pronounced cardiorenal protection, particularly in
high-risk patients with impaired kidney function. The phase 2a min-
erAlocorticoid Receptor antagonist Tolerability Study (ARTS) trial
showed that in patients with HFrEF and mild CKD, finerenone
(5.0–10.0 mg/d) had compared efficacy with that of spironolac-
tone (25 or 50 mg/d), with smaller increases in serum potassium
level and smaller decreases in estimated glomerular filtration
rate (eGFR).11 Further, the phase 2b ARTS-Diabetic Nephropathy
trial confirmed the safety of finerenone in patients with diabetic
kidney disease.12
The ARTS-HF (Clinicaltrials.gov Identifier: NCT01807221) study
was designed to compare the efficacy and safety of five different
treatment regimens of once-daily oral doses of finerenone with
eplerenone in patients with concomitant type 2 diabetes mellitus
(T2DM) and/or CKD, who presented in emergency departments
with worsening chronic HFrEF.
Methods
Study design
ARTS-HF has been described in detail elsewhere.13 Briefly, ARTS-HF
was a randomized, double-blind, active-comparator-controlled,
parallel-group, phase 2b, dose-finding study conducted at 173 centres
in 25 countries.7 The study protocol was developed by the steering
committee together with the sponsor (Bayer Pharma AG), and was
approved by independent ethics committees and/or institutional
review boards for all participating centres/countries before the study
began. The study was carried out in accordance with Good Clinical
Practice guidelines, the guiding principles of the Declaration of
Helsinki, and applicable local laws and regulations. All participating
patients gave written informed consent. Safety and tolerability were
monitored by an independent Data Safety Monitoring Board and a
central committee performed blinded adjudication of all hospitaliza-
tions and deaths.
Patients
Patients were recruited from June 2013 to August 2014 and were eli-
gible for inclusion in the study if they were at least 18 years old and
had worsening chronic HFrEF requiring hospitalization and treatment
with intravenous diuretics. They also had to have T2DM and/or CKD
(i.e. an eGFR of .30 mL/min/1.73 m2 in patients with T2DM and 30–
60 mL/min/1.73 m2 in patients without T2DM), have been receiving
treatment with evidence-based therapy for HF for at least the previous
3 months, and have a medical history of a left ventricular ejection frac-
tion of 40% or less within the previous 12 months. Patients receiving
treatment with spironolactone, eplerenone, renin inhibitors, or
potassium-sparing diuretics at presentation had to be able to discon-
tinue those treatments for 24 h before randomization (48 h for spirono-
lactone) and for the duration of the study treatment period. Further
details of the inclusion and exclusion criteria have been published
previously.13
Dosing, randomization, and masking
Randomization was carried out centrally by an interactive voice/web re-
sponse system and participants, investigators, and the sponsor’s clinical
team was blinded to treatment allocation. There were five preplanned
finerenone treatment arms and one eplerenone treatment arm. The
daily doses in the finerenone treatment arms (presented as ‘initial
dose  uptitrated dose’; see ‘Procedures’ section below) were
2.55, 510, 7.515, 1020, and 1520 mg. The initial dose in
the eplerenone treatment arm was 25 mg every second day; this could
be increased to 25 mg once daily and then to 50 mg once daily if both
uptitration steps were performed. Uptitration of both study drugs and in
all dose groups was performed if serum potassium levels remained
≤5.0 mmol/L. Patients were initially randomized 1:1:1 during the
7 days following hospital presentation to 1 of the 2 lowest preplanned
finerenone doses (2.55 or 510 mg once daily) or eplerenone. The
Data Safety Monitoring Board assessed safety and tolerability after ran-
domization of 300 patients in January 2014 and decided that the three
remaining preplanned finerenone treatment arms could be introduced
into the study. The randomization scheme was adapted to achieve a final
randomization ratio of 1:1.5 between each finerenone dose group and
the eplerenone group.
G. Filippatos et al.2106
Procedures
Finerenone or eplerenone was administered on top of standard therapy
for HF. The planned treatment duration was 90 days, with an additional
follow-up period after the cessation of study drug for 30 days. The titra-
tion protocol was the same in all treatment groups: if blood potassium
concentration was 5.0 mmol/L or less, the initial dose of finerenone or
eplerenone was uptitrated at the end of the acute/vulnerable phase
(Day 30), and an additional uptitration (eplerenone) or sham uptitration
(finerenone) was performed at Day 60. Treatment with the study drug
was stopped if the patient had a confirmed blood potassium concentra-
tion of 5.6 mmol/L or more.
Outcomes
The primary study objective was to investigate the efficacy (percentage
of responders; i.e. the number of patients with a decrease in plasma
N-terminal pro-B-type natriuretic peptide (NT-proBNP) level of
.30% from baseline to Day 90) and safety of different oral doses of
finerenone given once daily.
Further exploratory efficacy endpoints included: (i) a composite end-
point of death from any cause, cardiovascular hospitalization, or emer-
gency presentation for worsening chronic HF until Day 90; (ii) change in
efficacy biomarkers (B-type natriuretic peptide, NT-proBNP, galectin 3,
and N-terminal procollagen III propeptide); (iii) change in scores on
health-related quality-of-life (QoL) questionnaires [the Kansas City Car-
diomyopathy Questionnaire (KCCQ) and the five-dimension European
Quality of Life Questionnaire (EuroQoL)]. Clinical endpoints have been
adjudicated by the event committee.
Effects on the following safety parameters were assessed: (i) biomar-
kers of organ injury (troponin T and cystatin C); (ii) vital signs; (iii) la-
boratory parameters (including potassium and serum creatinine
concentrations, and eGFR; (iv) incidence of adverse events including
those of special interest (i.e. an increase in serum potassium concentra-
tion to at least 5.6 mmol/L leading to discontinuation or emergency
presentation for worsening chronic HF after starting treatment with
the study drug).
Statistical analysis
Analyses were performed in three data sets: the safety-analysis set, full-
analysis set, and per-protocol set (see Supplementary material online,
Appendix). The primary endpoint was assessed in the full-analysis set
(with missing data imputed using the last observation carried forward
(LOCF): the highest NT-proBNP value from the premature discontinu-
ation and follow-up measurements were used in such cases); a support-
ive analysis was performed in the per-protocol set and several sensitivity
analyses on the imputation method (including on-treatment LOCF, ob-
served case analysis, and random imputation) were performed in the
full-analysis set. For the primary endpoint, each finerenone group was
compared with the eplerenone group using separate Chi-squared tests
with continuity correction. In both cases, a one-sided significance level
of 5% was applied. For each contingency table, estimated and two-sided
90% CIs were provided for each treatment groups and treatment
differences.
Patients who died prior to Day 90, or who permanently discontinued
study drug (≥5 consecutive days) after cardiovascular hospitalization or
after emergency hospital presentation for worsening chronic HF, were
considered nonresponders to avoid biasing the primary efficacy analysis
towards treatment responders.
The composite mortality/morbidity endpoint, its individual compo-
nents, and cardiovascular mortality were assessed using the life-table
and Kaplan–Meier methods. Differences between the finerenone and
eplerenone groups were assessed using the log-rank test. This is an
exploratory study, i.e. no confirmatory testing on the primary efficacy
variable or other variables was performed. Further details of the statis-
tical methods have been reported elsewhere.10
Results
Patients
The disposition of the patients throughout the study is shown in
Figure 1. Baseline characteristics were broadly similar across the
treatment groups (Table 1). Of the 1066 randomized patients,
72.8% completed the study and 9.4% withdrew consent (Figure 1;
see Supplementary material online, Table S1); the majority was
receiving recommended pharmacologic therapy for chronic HF.
Mean age ranged from 69.2 to 72.5 years in different treatment groups
(standard deviation 9.7–10.6 years). The median NT-proBNP concen-
tration at baseline was highest in the eplerenone group (5331 [range
148–47 774] pg/mL) and lowest in the finerenone 1520 mg dose
group (3750 [range 144–45 375] pg/mL). The median BNP concentra-
tion at baseline was highest in the finerenone 2.55 (715 pg/mL) and
lowest in the finerenone 510 mg dose group (559 pg/mL).
Dosing
Maximum doses were reached in 77.3% of patients in the finerenone
2.55 mg group, 79.1% of the 510 mg group, 81.4% of the
7.515 mg group, 77.5% of the 10–20 mg group, and 73.6% of
the 1520 mg group. In the eplerenone group, 64.3% of patients
reached the 50 mg daily dose. The average daily dose of eplerenone
was 38.6 mg.
Efficacy
Primary efficacy endpoint
The proportion of patients who had an NT-proBNP level decrease
of .30% at Day 90 compared with baseline was similar in the finer-
enone groups and the eplerenone group in the full-analysis set
(Figure 2) and the per-protocol set (see Supplementary material
online, Figure S1). The proportions of patients who had an
NT-proBNP level decrease of .30% at Day 30 and at Day 60 com-
pared with baseline were also not statistically different across the
groups (see Supplementary material online, Figure S2). Sensitivity
analyses on the imputation method indicated no relevant effect
on the results by the imputation method (see Supplementary mater-
ial online, Table S2).
Summary statistics for the NT-proBNP concentration ratio Day
90: baseline was similar between the groups (see Supplementary
material online, Table S3). A mixed-effect model with factors treat-
ment group, comorbidities, MRA use at emergency presentation,
region, atrial fibrillation, time, treatment*time, and baseline
NT-proBNP value as covariates also showed no differences be-
tween the eplerenone group and the finerenone groups (see Sup-
plementary material online, Table S4).
Further exploratory efficacy endpoints
The incidence of the composite endpoint at Day 90 was lower in all
finerenone groups compared with the eplerenone group, except for
the finerenone 2.55 mg group (Figure 3 and see Supplementary
material online, Table S5). The incidence of the composite endpoint
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in the 1020 mg dose group was nominally improved vs. that in the
eplerenone group (hazard ratio, HR: 0.56; 95% CI: 0.35, 0.90; P ¼
0.02). Similar findings for the 1020 mg dose group vs. eplerenone
were observed for the individual components of death from any
cause [HR: 0.13 (95% CI: 0.02, 1.07)], cardiovascular hospitalization
[HR: 0.56 (95% CI: 0.34, 0.93)] and emergency presentation to hos-
pital for worsening chronic HF [HR: 0.58 (95% CI: 0.33, 1.02)]; see
Supplementary material online, Table S5. The HRs were adjusted for
log-transformed baseline NT-proBNP in a post hoc analysis, leading
to only slightly higher values (see Supplementary material online,
Table S6).
The changes in concentrations of galectin 3 and N-terminal pro-
collagen III peptide from baseline to Day 90 were small. Mean scores
on the KCCQ and the EuroQoL Questionnaire improved at Day 90
compared with baseline in all treatment groups (see Supplementary
material online, Table S7).
Safety
All doses of finerenone had a similar safety profile to that of epler-
enone. Incidences of treatment-emergent adverse events were simi-
lar between the eplerenone group and all finerenone dose groups
(Table 2). Hyperkalaemia (serum potassium concentration
≥5.6 mmol/L) at any time post baseline was observed in 44 patients
(4.3%), with a balanced distribution among the finerenone dose
groups and the eplerenone group. Five patients (1/212 (0.5%) in
the eplerenone group, and 1/164 (0.6%) and 3/160 (1.9%) in the
Figure 1 Patient disposition. All patients from the safety-analysis set were considered for the full-analysis set if they had baseline and at least one post
baseline plasma N-terminal pro-B-type natriuretic peptide level value or who died, experienced permanent (≥5 consecutive days) withdrawal of study
drug after cardiovascular hospitalization, or after emergency presentation for worsening chronic heart failure. The per-protocol set comprised all
patients from the full-analysis set with valid plasma NT-proBNP data at visit 7 (Day 60+2) or later and no major protocol deviations.
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finerenone 7.515 and 1520 mg dose groups, respectively) had
a serum potassium concentration .6.0 mmol/L at any time post
baseline. Mean change from baseline to Day 90 in serum potassium
concentration was greater in the eplerenone group (+0.262 mmol/
L) than in each of the finerenone dose groups (+0.119–
0.202 mmol/L; Figure 4).
Mean systolic blood pressure decreased by ,3 mmHg from
baseline to Day 90 in all treatment groups. The size of the decrease
was similar in the eplerenone group and the finerenone 510 mg,
7.515 and 1020 mg dose groups. No clear dose relationship
was observed in the finerenone groups (see Supplementary material
online, Table S8).
Mean eGFR (as measured using the modification of diet in renal
disease equation) increased slightly from baseline to Day 90 in the
two lowest finerenone groups and decreased in the other groups
(see Supplementary material online, Table S9). The proportion of
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Table 1 Patient demographics and clinical characteristics (safety-analysis set)
Parameter Eplerenone
n5 221
Finerenone
2.55 mg
n5 172
Finerenone
510 mg
n 5 163
Finerenone
7.515 mg
n 5 167
Finerenone
1020 mg
n 5 169
Finerenone
1520 mg
n 5 163
Total
N 5 1055
Mean age (SD) (years) 72.4 (9.9) 72.5 (9.7) 71.8 (10.6) 69.3 (9.8) 71.3 (10.23) 69.2 (10.2) 71.2 (10.1)
Male sex, n (%) 170 (76.9) 135 (78.5) 126 (77.3) 124 (74.3) 128 (75.7) 132 (81.0) 816 (77.3)
Region, n (%)
Europe 169 (76.5) 130 (75.6) 128 (78.5) 131 (78.4) 133 (78.7) 132 (81.0) 823 (78.0)
North America 14 (6.3) 9 (5.2) 8 (4.9) 15 (9.0) 13 (7.7) 10 (6.1) 69 (6.5)
Asia 7 (3.2) 7 (4.1) 4 (2.5) 5 (3.0) 7 (4.1) 7 (4.3) 37 (3.5)
Other 31 (14.0) 26 (15.1) 23 (14.1) 16 (9.6) 16 (9.5) 14 (8.6) 126 (11.9)
New York Heart Association functional class before worsening, n (%)
II 84 (38.0) 65 (37.8) 49 (30.1) 71 (42.5) 79 (46.7) 62 (38.0) 410 (38.9)
III 121 (54.8) 92 (53.5) 98 (60.1) 89 (53.3) 80 (47.3) 89 (54.6) 569 (53.9)
IV 16 (7.2) 15 (8.7) 16 (9.8) 7 (4.2) 10 (5.9) 12 (7.4) 76 (7.2)
Risk factors, (%)
Type 2 diabetes mellitus (without CKD) 55 (24.9) 39 (22.7) 36 (22.1) 49 (29.3) 48 (28.4) 53 (32.5) 280 (26.5)
Type 2 diabetes mellitus with CKD 84 (38.0) 68 (39.5) 71 (43.6) 59 (35.3) 60 (35.5) 56 (34.4) 398 (37.7)
Chronic kidney disease (without T2DM) 82 (37.1) 63 (36.6) 55 (33.7) 57 (34.1) 61 (36.1) 52 (31.9) 370 (35.1)
Ischaemic heart disease 147 (66.5) 114 (66.3) 109 (66.9) 111 (66.5) 104 (61.5) 94 (57.7) 679 (64.4)
Arterial hypertension 158 (71.5) 127 (73.8) 121 (74.2) 121 (72.5) 127 (75.1) 121 (74.2) 775 (73.5)
Atrial fibrillation, ECG at baseline 107 (48.4) 64 (37.2) 70 (42.9) 61 (36.5) 68 (40.2) 62 (38.0) 432 (40.9)
Heart failure medications, n (%)
Angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker at baseline
173 (78.3) 131 (76.2) 129 (79.1) 130 (77.8) 127 (75.1) 134 (82.2) 824 (78.1)
b-Blocker at baseline 189 (85.5) 137 (79.7) 141 (86.5) 146 (87.4) 148 (87.6) 146 (89.6) 907 (86.0)
Mineralocorticoid receptor antagonist at index
emergency presentation
92 (41.6) 72 (41.9) 73 (44.8) 74 (44.3) 75 (44.4) 69 (42.3) 455 (43.1)
Median N-terminal pro-B-type natriuretic peptide
concentration (pg/mL)
5331 5000 4386 4085 4543 3750 4517
Median B-type natriuretic peptide concentration,
(pg/mL)
645 715 559 572 646 570 625
Mean potassium concentration (SD), (mmol/L) 4.1 (0.5) 4.1 (0.5) 4.2 (0.5) 4.2 (0.4) 4.1 (0.5) 4.2 (0.5) 4.1 (0.5)
Mean eGFRa (SD), (mL/min 1.73 m2) 52 (18) 52 (16) 52 (16) 55 (20) 53 (17) 55 (19) 53 (18)
eGFRa, ≤60 mL/min 1.73 m2, n (%) 159 (72) 120 (70) 127 (78) 116 (69) 120 (71) 110 (67) 752 (71)
Mean creatinine concentration (SD) (mg/dL) 1.5 (0.4) 1.5 (0.4) 1.5 (0.4) 1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 1.4 (0.4)
Mean urinary albumin:creatinine ratio (SD) (g/kg) 52 (5) 50 (5) 43 (5) 41 (5) 41 (5) 39 (5) 45 (5)
High/very high albuminuria, n (%) 124 (56.1) 97 (56.3) 80 (49.1) 85 (50.9) 95 (56.2) 77 (47.3) 558 (52.9)
Mean systolic blood pressure (SD) (mmHg) 121 (19) 119 (16) 118 (14) 119 (17) 116 (17) 117 (17) 119 (17)
Mean heart rate (SD) (beats/min) 75 (14) 73 (13) 73 (13) 74 (12) 74 (12) 74 (13) 74 (13)
Mean ejection fraction (SD) (%) 29.8 (7.5) 29.3 (7.8) 28.7 (7.4) 28.5 (7.4) 29.0 (8.0) 29.0 (7.5) 29.1 (7.6)
SD, standard deviation.
aEstimated glomerular filtration rate was calculated using the modification of diet in renal disease equation.
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Figure 2 Proportion of patients with a decrease of .30% in plasma N-terminal pro-B-type natriuretic peptide concentration from baseline at
Day 90 (full-analysis set). Patients who died prior to Day 90 or who experienced permanent (≥5 consecutive days) withdrawal of study drug after
a cardiovascular hospitalization or emergency presentation for worsening chronic heart failure were counted as nonresponders for the primary
efficacy analysis.
Figure 3 Mortality/morbidity outcomes in patients with worsening chronic heart failure with reduced ejection fraction receiving eplerenone or
different doses of finerenone. Cumulative event rates of the composite endpoint of death from any cause, cardiovascular hospitalization, or emer-
gency presentation for worsening chronic heart failure in the full-analysis set.
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patients experiencing a decrease in eGFR of ≥25, ≥30, ≥40, and
≥57% was low across all groups (see Supplementary material
online, Table S10) and there was no statistically significant change
in heart rate between groups (see Supplementary material online,
Table S11).
There were five renal events leading to hospitalization: two in the
eplerenone group and one each in the finerenone 2.55, 7.515,
and 1520 mg dose groups.
Discussion
Mineralocorticoid receptor antagonists have not been systematically
studied in patients with worsening chronic HFrEF who require
emergency admission to hospital. However, evidence from the
use of MRAs in other patient groups1,2,14 and the intense neurohor-
monal activation in patients with worsening HF3,15 suggests that the
MR may be an important therapeutic target in this population with
very high morbidity and mortality despite current therapy.
ARTS-HF is the first clinical trial to compare the novel nonsteroi-
dal MRA finerenone with eplerenone in this population with a high
unmet medical need i.e. patients with worsening HFrEF requiring
emergency treatment and who also have DM and/or CKD. This per-
iod of acute worsening is a crucial time for treatment of patients
with HFrEF because mortality and morbidity are known to increase
following emergency presentation. In this high-risk population, finer-
enone was well tolerated with a safety profile comparable with that
of eplerenone. The proportion of patients who had an NT-proBNP
level decrease of .30% from baseline to Day 90 was similar in the
finerenone and eplerenone groups. Although the absolute decrease
in NT-proBNP was highest in the eplerenone group, this may be due
to the fact that this group had the highest NT-proBNP levels at base-
line. However, the incidences of the exploratory composite end-
point of death from any cause, cardiovascular hospitalization, or
emergency presentation for worsening HF at Day 90 were lower
in most finerenone groups compared with eplerenone. Changes
in other efficacy biomarkers and QoL questionnaires were similar
between finerenone and eplerenone groups.
Eplerenone was chosen as the active comparator for ARTS-HF
because it was considered to be more suitable than spironolactone
for patients with DM (owing to the metabolic effects of
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Table 2 Incidence of treatment-emergent adverse events and hyperkalaemia in patients with worsening chronic heart
failure with reduced ejection fraction receiving eplerenone or finerenone (safety-analysis set)
Adverse event parameter Incidence, n (%)
Eplerenone
n5 221
Finerenone
2.55 mg
n5 172
Finerenone
510 mg
n5 163
Finerenone
7.515 mg
n 5 167
Finerenone
1020 mg
n 5 169
Finerenone
1520 mg
n 5 163
Total
N 5 1055
Any treatment-emergent adverse
event
170 (76.9) 132 (76.7) 124 (76.1) 105 (62.9) 120 (71.0) 128 (78.5) 779 (73.8)
Any treatment-emergent serious
adverse event
77 (34.8) 72 (41.9) 47 (28.8) 52 (31.1) 46 (27.2) 57 (35.0) 351 (33.3)
Discontinuation due to
treatment-emergent adverse event
32 (14.5) 21 (12.2) 25 (15.3) 25 (15.0) 17 (10.1) 21 (12.9) 141 (13.4)
Study drug-related
treatment-emergent adverse event
39 (17.6) 34 (19.8) 28 (17.2) 32 (19.2) 27 (16.0) 29 (17.8) 189 (17.9)
Study drug-related
treatment-emergent serious
adverse event
9 (4.1) 10 (5.8) 7 (4.3) 11 (6.6) 6 (3.6) 11 (6.7) 54 (5.1)
Treatment-emergent adverse events
of special interest
44 (19.9) 38 (22.1) 28 (17.2) 34 (20.4) 25 (14.8) 35 (21.5) 204 (19.3)
Hyperkalaemia from baseline to Day 30a
Potassium concentration
≥5.6 mmol/L
1/178 (0.6) 1/136 (0.7) 2/138 (1.4) 0/142 (0.0) 2/144 (1.4) 1/137 (0.7) 7/875 (0.8)
Potassium concentration
.6.0 mmol/L
0/178 (0.0) 0/136 (0.0) 0/138 (0.0) 0/142 (0.0) 0/144 (0.0) 1/137 (0.7) 1/875 (0.1)
Hyperkalaemia at any time post baselinea
Potassium concentration
≥5.6 mmol/L
10/212 (4.7) 6/165 (3.6) 6/157 (3.8) 6/164 (3.7) 6/165 (3.6) 10/160 (6.3) 44/1023 (4.3)
Potassium concentration
.6.0 mmol/L
1/212 (0.5) 0/165 (0.0) 0/157 (0.0) 1/164 (0.6) 0/165 (0.0) 3/160 (1.9) 5/1023 (0.5)
Emergency presentation for
worsening chronic heart failure
40 (18.1) 33 (19.2) 23 (14.1) 26 (15.6) 19 (11.2) 30 (18.4) 171 (16.2)
aIncidence of hyperkalaemia is presented as n/n with available data (%).
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spironolactone)16,17 or CKD (owing to the safety profile of spirono-
lactone in patients with moderate CKD)13,18 Given that .70% of
the study population had an eGFR ≤60 mL/min/1.73 m2 at baseline,
the starting dose of eplerenone chosen (25 mg every second day) is
in line with the recommended starting dose of eplerenone in stable
patients with HFrEF and CKD.2,19
Overall, patients in the finerenone 1020 mg dose group had
the greatest reduction in the composite outcome including death
from any cause, cardiovascular hospitalization, or emergency pres-
entation to hospital, compared with patients in the eplerenone
group (HR: 0.56; 95% CI: 0.35, 0.90).
Together, these observations suggesting a better outcome in the
finerenone 1020 mg group compared with the other finerenone
groups and the eplerenone group, combined with a safety profile
that is comparable with that in the other groups, indicate that the
10 mg once-daily dose of finerenone, uptitrated to 20 mg after 30
days, would provide the best balance of safety and efficacy for
further investigation in larger clinical trials.
There are mechanisms that may explain the decrease in the
clinical composite endpoint in the finerenone (1020 mg) group.
Finerenone has a unique pharmacodynamic profile, which is consid-
ered to be the consequence of different physicochemical properties
in comparison with steroidal MRAs. Physicochemical drug proper-
ties have a strong impact on plasma protein binding, vascular trans-
port, and tissue penetration and distribution. Moreover, finerenone
has a different mode of mineralocorticoid receptor inactivation
compared with steroidal MRAs,9 which may lead to a pronounced
suppression of downstream gene expression leading to hypertrophy
and, thus, improved organ protection.10 However, the reason why
outcomes seem to be improved, particularly in the finerenone
1020 mg compared with the 1520 mg group, is unclear at
this stage.
Both finerenone and eplerenone were well tolerated overall, with
a similar rate of adverse events across all study groups and a low
incidence of renal events leading to hospitalization. Overall,
4.3% of patients experienced serum potassium concentration
≥ 5.6 mmol/L. A potassium concentration .6.0 mmol/L was ob-
served in only five patients (0.5%), with no such elevations observed
in the finerenone 2.55 mg, 510 and 1020 mg dose groups.
Although MRA use has been limited by safety concerns in patients
with HF and concomitant diabetes or renal impairment, previous stud-
ies have shown that their clinical benefits are maintained in these pa-
tient groups. In RALES,20 spironolactone efficacy was maintained in
patients with an eGFR ,60 mL/min/1.73 m2. In EMPHASIS-HF, the
cumulative rate of the primary endpoint (HF hospitalization or cardio-
vascular mortality) remained significantly reduced in the eplerenone
group compared with the placebo group in the subset of patients
with DM or renal dysfunction.6 In EPHESUS, a history of DM and an
eGFR ≤60 mL/min/1.73 m2 were each identified as risk factors for de-
veloping a serum potassium concentration ≥6.0 mEq/L, but did not
alter the cardiovascular benefit of eplerenone.21
Introduction of a novel neurohormonal blocking agent into clin-
ical practice in patients with HFrEF already on standard therapy may
be challenging, particularly when the new agent should replace a
cornerstone drug of this regimen. In the present study, 43% of pa-
tients were already on MRA therapy with spironolactone or epler-
enone at baseline. In those patients, spironolactone and eplerenone
were discontinued 48 or 24 h before randomization, respectively.
This strategy was well tolerated and, thus, ARTS-HF provides
some practical insights into how these agents should be introduced
Figure 4 Mean change in serum potassium concentration from baseline to Day 90 in patients with worsening chronic heart failure with reduced
ejection fraction receiving eplerenone or different doses of finerenone. Changes were assessed by analysis of covariance with the factors treat-
ment group, comorbidities, mineralocorticoid receptor antagonist use at emergency presentation to hospital, region, and the baseline value as
covariates.
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in the clinical practice. Pending the results of further clinical studies,
it is possible that this non-steroidal MRA will provide an alternative
therapy option for patients with HF in particular in those who are at
high risk of developing hyperkalaemia.
Study limitations
The primary efficacy endpoint in ARTS-HF was based on a surrogate
marker of efficacy: the proportion of patients who experienced a
.30% reduction in NT-proBNP levels. Prospective studies showed
that decreases in plasma NT-proBNP concentrations of 30% or
more correlate with improved prognosis22 – 32 but also changes in
natriuretic peptides by several drugs were not related to improved
outcome in clinical trials.33 – 35 N-terminal pro-B-type natriuretic
peptide levels may be increased in patients with atrial fibrillation
and HF compared with those without atrial fibrillation. A factor to
account for atrial fibrillation was included when performing an ana-
lysis of covariance for the absolute change in NT-proBNP levels.
There were differences in NT-proBNP at baseline between the
groups, which were also considered within the ANCOVA for abso-
lute change in NT-proBNP levels by adjusting for logarithmized
baseline NT-proBNP.10
In addition, the composite of death from any cause, cardiovascu-
lar hospitalizations, or emergency presentations for worsening HF
was only a secondary endpoint and the observed event rate was
low. Therefore, these findings need to be confirmed by subsequent
studies with higher event rates, and longer treatment duration and
follow-up, in order to draw firm conclusions.
Conclusions
ARTS-HF is the first clinical trial to compare the novel nonsteroidal
MRA finerenone with eplerenone in a unique and vulnerable patient
population. In patients with worsening HFrEF requiring hospitaliza-
tion and who also had DM and/or CKD, finerenone reduced levels
of NT-proBNP to a similar extent to that of eplerenone with a good
safety profile. The present study provides the grounds for the fur-
ther evaluation of this novel non-steroidal MRA in the setting of a
phase 3 study and also indicates that 1020 mg is the most suitable
dosage scheme to be tested.
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